OS Therapies Inc 2Q 2026: Net loss $8.63M, EPS $(0.20) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.OS Therapies Inc reported a widened Q2 2026 net loss of $8.63M, or $(0.20) EPS, compared to $4.54M in the prior year. For the first half of 2026, the consolidated net loss reached $19.03M. Despite financial losses, the company highlighted clinical success with its OST-HER2 therapy meeting Phase IIb primary endpoints. OS Therapies is engaging with regulatory bodies for future submissions and has secured financing through direct offerings and notes to support ongoing R&D and trial activities.
OS Therapies Inc reported a second-quarter 2026 net loss of $8.63M, or $(0.20) per diluted share, compared with a net loss of $4.54M, or $(0.19) per share in the year-ago quarter. For the six months ended 2026 the company recorded a consolidated net loss of $19.03M, or $(0.46) per share, versus a six-month loss per share of $(0.35) in the prior year period.
Financial Highlights
- Net loss: $8.63M for 2Q 2026, compared with a net loss of $4.54M in 2Q 2025 (loss widened ~90% YoY).
- Six-month net loss: $19.03M for 6M 2026 (consolidated).
- Diluted EPS: $(0.20) for 2Q 2026 versus $(0.19) in 2Q 2025; six-month diluted EPS $(0.46) versus $(0.35) year-ago (approximately 31% larger loss per share year-over-year for six months).
Business Highlights
- Clinical Milestone — OST-HER2: Phase IIb met its primary endpoint, showing a 2.5-year overall survival of 75% versus a 47% historical control, with the therapy reported as well tolerated.
- Regulatory Pathway & Plans: Ongoing engagements with the FDA, MHRA and EMA; company anticipates a Type C meeting with the FDA in September 2026 and plans MAA submissions in Q1 2027.
- Pipeline Expansion: Continued development of the OST-tADC antibody‑drug conjugate platform and exploration of OST-HER2 combination regimens with HER2 antibodies for other solid tumors.
- Operational and R&D focus: Increased R&D spending to compile regulatory package data; VAT recovery activity reduced reported R&D costs and helped extend cash runway.
- Financing: Completed multiple financings, including a registered direct offering and secured notes, to fund ongoing clinical, regulatory and trial activities.
Original SEC Filing: OS Therapies Inc [ OSTX ] - 10-Q - Aug. 14, 2026